Hemodialysis, Kidney Failure, Chronic
Conditions
Brief summary
To verify the efficacy of recombinant erythropoiesis stimulating protein injection (CHO cell) in hemodialysis patients with chronic renal failure anemia maintenance treatment is not inferior to yibio.
Detailed description
In this phase 3, open label, active comparator parallel controlled study, patients were randomly assigned to two study groups: one active comparator control group (Human Erythropoietin Injection , maintaining the same dose and frequency administrated in the sceening period ), and experimental groups (50μg, once every two weeks). All the patients were administered intravenously for 32 weeks and were evaluated the efficacy, safety and pharmacokinetic characteristics. During the whole study period, dosage adjustment was not allowed in the first 4 weeks, while in the remaining trial period dosage adjustment was allowed once every two weeks if necessary.
Interventions
DRUGHuman Erythropoiesis Injection (CHO cell)
Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Sponsors
Shenyang Sunshine Pharmaceutical Co., LTD.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Volunteer as a subject must understand the study procedure and sign the informed consent form; * 18 years old ≤ age ≤ 75 years old when sign ICF, gender is not limited; * Patients diagnosed with chronic renal failure anemia were receiving maintenance hemodialysis for at least 3 months and 2-3 times a week; The dialysis frequency was stable and there was no change in the dialysis plan throughout the study period; * Before enrollment, patient being treated short-acting EPO stabilization therapy for at least 12 weeks, the average concentration of hemoglobin in the screening period is in the range of 100\ 120 g/L (including both ends), and the difference is less than 10g/L; * Iron status and dialysis status were evaluated within 4 weeks before enrollment to meet the following requirements: Transferrin saturation (TSAT) ≥20% and serum ferritin (SF) ≥200 μg/L; Dialysis parameters: urea clearance index spKt/V≥1.2; * Subjects agree to use reliable contraceptives by themselves and their spouses from the screening period to within 3 months after the end of the study;
Exclusion criteria
* Allergic to the investigational drug or any ingredient in the investigational drug or has had a severe allergic reaction to the drug in the past; * Except of renal anemia, there are other diseases that cause chronic anemia (such as sickle cell anemia, myelodysplastic syndrome, hematological malignancies, myeloma, hemolytic anemia, pure red blood cell aplastic anemia), blood systemic disease or coagulopathy; * Patients who have received or plan to have a kidney transplant during the study period, or who plan to have other surgical procedures during the study period (mainly major surgeries, except those with low blood loss that do not affect Hb concentration); * Patients with acute or chronic blood loss (such as upper gastrointestinal bleeding, etc.) within 3 months prior to enrollment were excluded from the scope of hemorrhage caused by minor surgeries such as temporary vascular access required by clinical medical procedures; * Patiernts who was suffering from malignant hypertension or poor control of blood pressure (systolic blood pressure \>180 mmHg or diastolic blood pressure \>100 mmHg); * The following conditions (including but not limited to) occurred in the laboratory examination during the screening period, and the investigator judged that the participants were not eligible for inclusion: a) Patients who were positive for HBsAg, anti-HIV, anti-HCV, and Treponema pallidum antibodies; b) The aspartate aminotransferase or alanine aminotransferase is greater than 3 times the upper limit of normal; c) Serum albumin \< 35g/L; * Patiernts who was suffering from severe secondary hyperparathyroidism (sustained blood iPTH/PTH \>1000 ng/L); * Patients with previous thromboembolic disease (excluding luminal infarction), history of severe hematopoietic system, and high clotting tendency; * Patiernts with severe cardiovascular and cerebrovascular disease, severe or unstable coronary artery disease, heart failure (NYHA class III or IV), temporary vascular access, or myocardial infarction or stroke within 3 months before enrollment; * A history of malignant neoplasms, except for: basal cell or squamous cell carcinoma of the skin determined to be cured or no recurrence within 5 years, with radical excision, or carcinoma in situ at any site; * The researchers identified those with severe infectious disease or chronic, uncontrolled inflammation within the first four weeks of enrollment; * All epilepsy or epilepsy history except of childhood febrile seizures, post-traumatic or abstinence single seizures; * Those who have received androgen therapy or who have received blood transfusion therapy within the past 8 weeks before enrollment; * Patients who had a pacemaker for more than 5 years; If no more than 5 years of cardiac pacemaker working status assessment and test unqualified; * 3 months as a subject to participate in other new drug clinical trials or to the group when the withdrawal time is shorter than the five half-life of the test drug (whichever is the longest of the two); * Subjects were in the middle of pregnancy or lactation at the time of enrollment; * Alcohol, drug or drug addicts; * Other conditions that may not be suitable for the study as determined by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hemoglobin concentration | 25th-32nd week | the amount of change in mean Hb concentration compared with baseline Hb concentration during the evaluation period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the ratio of subjects who are adjusted | for 32 weeks | the ratio of subjects who are adjusted during the treatment and evaluation period |
| incidence of Human Erythropoietin antibodies and anti-rESP antibodies | for 32 weeks | incidence of Human Erythropoietin antibodies and anti-rESP antibodies |
| Maximum Plasma Concentration (Cmax) | for 32 weeks | the Cmax of rESP in patients with long-term medication |
| maintenance rate | 25th-32nd week | the proportion of subjects whose average Hb concentration remained within the target range during the evaluation period |
| proportion of subjects | for 32 weeks | the proportion of subjects whose range of dose adjustments decreased or increased by 25% still did not reach 100-120 g/L (both ends) |
| proportion of times | 25th-32nd week | the proportion of times the measured Hb concentration remains within the target range during the subject evaluation period |
| Area Under the Curve (AUC) | for 32 weeks | the AUC of rESP in patients with long-term medication |
| average hemoglobin concentration | 25th-32nd week | the mean Hb concentration during the evaluation period |
| mean reticulocyte count | 25th-32nd week | changes in mean values of reticulocyte compared to baseline values during the evaluation period |
| mean red blood cell count | 25th-32nd week | changes in mean values of red blood cell count compared to baseline values during the evaluation period |
| adverse events | for 32 weeks | the type, proportion and severity of adverse events |
| number of dose adjustments | for 32 weeks | the number of dose adjustments used by the subject during the treatment and evaluation period |
| average weekly dose | 25th-32nd week | the average weekly dose of the drug during the evaluation period |
Countries
China
Contacts
Primary ContactGang Tong, MD
Outcome results
None listed